Methods for determining ldl cholesterol treatment

Abstract

Disclosed is a personalized diagnostic and treatment solution for cardiovascular disease. The invention comprises an extended CVD risk assessment panel, combining tests for traditional and new important risk markers, and methods for devising a personalized treatment plan for a patient via the use of a CVD diagnosis and treatment protocol algorithm. The new important risk markers include HDL subpopulation profile by two-dimensional gel-electrophoresis, plasma sterols, direct measurement of sdLDL-C, determination of CRP molecular forms, glycated albumin as a percentile of total albumin, and other specialized testing pertaining to apolipoprotein E and Factor V Leiden genotyping, NT-proBNP and adiponectin. This solution provides a more complete risk assessment of an individual than merely measuring traditional CVD risk markers, and enables the healthcare practitioner to optimize therapy for patients with or without established CVD. This solution presents the advantages of greater accuracy, savings in time and cost over existing testing and treatment methods.

We claim: 
     
         1 . A CVD risk panel, comprising
 a) at least one test for total cholesterol,   b) least one test for total triglyceride,   c) at least one test for lipoprotein particles, said at least one test for lipoprotein particles being for at least one test for each of the following: direct high density lipoprotein cholesterol, HDL subparticle fractionation by two-dimensional gel electrophoresis, direct low density lipoprotein cholesterol, direct small dense LDL cholesterol, percentage of LDL cholesterol as small dense LDL cholesterol, lipoprotein (a), and non-HDL cholesterol and total cholesterol/HDL cholesterol ratio,   d) one test for apolipoproteins,   e) at least one test for markers of diabetes, said at least one test for markers of diabetes being for at least one test for each of the following: insulin, albumin, glycosylated hemoglobin, and glycated albumin,   f) at least one test for plasma sterols, said at least one test for plasma sterols being for at least one test for each of the following: lathosterol, desmosterol, campesterol, beta-sitosterol, and cholestanol,   g) at least one test for inflammatory markers, said at least one test for inflammatory markers being for at least one test for each of the following: C reactive protein and lipoprotein associated phospholipase A2,   h) at least one test for genetic testing, said at least one test for genetic testing being for at least one test for each of the following: apolipoprotein E genotype, and factor V Leiden genotype, and   i) at least one test for secondary causes of high cholesterol, said at least one test for secondary causes of high cholesterol being for at least one test for each of the following: creatinine, blood urea nitrogen, creatine kinase, liver transaminases, alkaline phosphase, thyroid stimulating hormone, and uric acid.